Nudging Providers to Curtail Dangerous Opioid Prescribing: A Trial to Investigate Mechanisms
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04628832|
Recruitment Status : Not yet recruiting
First Posted : November 16, 2020
Last Update Posted : November 17, 2020
|Condition or disease||Intervention/treatment||Phase|
|Opioid Use||Behavioral: PMP Use Mandate Letter Behavioral: Prescribing Information Letter Behavioral: Prescribing Information + PMP Use Mandate Letter||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||12000 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Nudging Providers to Curtail Dangerous Opioid Prescribing: A Trial to Investigate Mechanisms|
|Estimated Study Start Date :||December 2020|
|Estimated Primary Completion Date :||March 2021|
|Estimated Study Completion Date :||January 2022|
|Experimental: PMP Use Mandate||
Behavioral: PMP Use Mandate Letter
A letter with reminders about the mandate to check the PMP when prescribing opioids.
|Experimental: Prescribing Information||
Behavioral: Prescribing Information Letter
A letter with information about the prescriber's patients who received co-prescriptions. The letters will provide clinical background on the harms of co-prescribing and encourage prescribers to avoid co-prescribing in the future.
|Experimental: Prescribing Information + PMP Use Mandate||
Behavioral: Prescribing Information + PMP Use Mandate Letter
A letter combining the content of the PMP Use Mandate Letter and the Prescribing Information Letter. This letter will remind prescribers about the PMP use mandate and provide information about the prescriber's patients who received co-prescriptions.
|No Intervention: Control / As-Usual|
- Rate of Prescribers Checking PMP [ Time Frame: 60 days ]Indicator for whether the prescriber checks the PMP at least once in the 60 days after the letters are sent.
- Rate of Prescribers Avoiding Co-prescriptions [ Time Frame: 60 days ]Indicator for whether the prescriber is responsible for zero co-prescriptions in the 60 days after the letters are sent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04628832
|Contact: Adam Sacarny, PhDemail@example.com|
|United States, Minnesota|
|Minnesota Board of Pharmacy|
|Minneapolis, Minnesota, United States, 55414|
|Contact: Barbara A Carter firstname.lastname@example.org|
|Minnesota Management and Budget Agency|
|Saint Paul, Minnesota, United States, 55155|
|Contact: Weston Merrick, MPA email@example.com|
|Sub-Investigator: Ian Williamson, MBA|
|Principal Investigator:||Adam Sacarny, PhD||Columbia University|
|Principal Investigator:||Mireille Jacobson, PhD||University of Southern California|
|Principal Investigator:||David Powell, PhD||RAND|